Euretos

Accelerating Translational Research for Breast Cancer This Breast Cancer Awareness Month, we honor Dr. James P. Allison and Dr. Tasuku Honjo, 2018 Nobel Laureates, for their discovery of Cancer Therapy by Inhibition of Negative Immune Regulation. Their groundbreaking work has revolutionized cancer treatment, leading to innovative immunotherapies that offer new hope to millions, including those battling breast cancer. The inhibition of immune checkpoints, as discovered by Allison and Honjo, has enabled therapies like Pembrolizumab and Atezolizumab to transform the treatment of Triple-Negative Breast Cancer (TNBC). Their research highlights how fundamental disease understanding can identify new therapeutic targets, ultimately advancing the precision and effectiveness of cancer treatments. At Euretos we are committed to accelerating translational research in drug discovery. Our data-driven research platform integrates cancer and healthy cell expression profiles, cancer mutations, and protein cellular localization data to identify novel targets for antibody-based therapeutics. By leveraging comprehensive datasets and advanced analytics, we empower scientists to uncover actionable insights that bridge the gap between discovery and clinical application. As we celebrate the strides made in immunotherapy in cancer, we invite translational scientists to harness the power of our platform to drive the next wave of breast cancer breakthroughs. Academic researchers get free access! Learn More: https://lnkd.in/dDfZc2Ys #BreastCancerAwareness #Immunotherapy #NobelPrize #DrugDiscovery #TranslationalResearch #CancerTherapeutics #HealthcareInnovation #ScientificResearch #AntibodyTherapeutics #Oncology

The Role of Translational Science in Breast Cancer Research   October is Breast Cancer Awareness Month. This year alone, over 2.3 million women will be diagnosed with invasive breast cancer worldwide and over 7% of cancer deaths are attributed to female breast cancer. These statistics are staggering and underline the urgency of translational science bridging the gap between preclinical discoveries and clinical solutions.   A recent case study highlights the importance of Olaparib (1), a PARP inhibitor, in treating metastatic breast cancer, even in patients with complex genetic backgrounds like double BRCA mutations. The patient experienced significant clinical benefit, underscoring how critical targeted therapies are for those with inherited mutations.   Translating promising therapies like olaparib from bench to bedside is challenging, especially when it comes to identifying the right cell models for preclinical studies. One of the ways in which the Euretos platform helps to address this challenge by enabling scientists to select the most appropriate cell lines based on specific expression profiles. This helps to ensure that preclinical research is more accurate and predictive of patient outcomes. If you're interested in learning how our platform can help identify the right cell models for your research, go to www.euretos.com. Academic researchers get free access. Read the full case study here: “Metastatic breast cancer with double heterozygosity for the BRCA1 and BRCA2 genes responding to olaparib: A case report.”  Oncol Lett. 2024 Apr 9;27(6):253. doi: 10.3892/ol.2024.14387. PMID: 38646498; PMCID: PMC11027096. #translationalresearch #cancerresearch #BreastCancerAwarenessMonth

In honor of Pain Awareness Month, we're highlighting groundbreaking insights into neuropathic pain and its underlying mechanisms. Recent single-cell RNA sequencing studies have unveiled the pivotal role of oligodendrocytes—glial cells responsible for myelin sheath formation—in conditions like neuralgia. By leveraging our data-driven research platform and biomedical knowledge graph, we've connected key findings on gene expression changes in oligodendrocytes and disruptions in steroid biosynthesis pathways. This integration accelerates hypothesis generation, uncovers novel therapeutic targets, and propels drug discovery forward. In the complex field of pain research, advanced data integration is essential, and we're committed to empowering researchers to develop more effective treatments faster. - www.euretos.com #translationalresearch #neuropathicpain #knowledgegraph

September is Pain Awareness Month – In this month’s Euretos Perspective we spotlight the often invisible, yet profound, impact of pain on millions of lives. Pain can be categorized into nociceptive, neuropathic, mixed, and nociplastic types, each requiring unique approaches for effective treatment. Neuropathic pain, in particular, is complex and challenging to diagnose. With its prevalence estimated at 7-8% in Europe, it significantly affects both physical and mental well-being. Advances in data-driven diagnostics, such as biomarker panels and predictive modeling, are revolutionizing how we understand and treat this condition. At Euretos, we’re leveraging data analytics to empower translational researchers in creating more personalized and effective treatments for neuropathic pain. This Pain Awareness Month, let's drive innovation forward to improve patient outcomes and transform pain management. #TranslationalResearch #PainAwarenessMonth #NeuropathicPain #DataDrivenResearch

Identifying Key Biomarkers for Psoriasis Treatment Response During Psoriasis Action Month, we want to highlight the findings from a recent study on potential biomarkers for evaluating treatment response in psoriasis. This study focused on three microRNAs (miRNAs): miR-155, miR-205, and miR-210, and explored their roles as biomarkers in determining the effectiveness of psoriasis treatments. - miR-205: Showed significantly higher levels in psoriasis patients compared to the control group, suggesting it could serve as a marker for treatment response. The upregulation of miR-205 in treated patients appears to correlate with lower TNF-α levels, indicating reduced inflammation and improved clinical outcomes. - miR-155: Identified as a promoter of inflammation in psoriasis, affecting cytokine levels such as IL-17, IL-23, and TNF-α, which are critical in the pathogenesis of the disease. - miR-210: Overexpressed in psoriasis patients, particularly under conditions of hypoxia, contributing to inflammation and keratinocyte proliferation. This miRNA's levels were associated with the Th1/Th17 axis, a key pathway in psoriasis pathology. Biomarkers are crucial in predicting how well a patient will respond to a specific treatment, identifying disease subtypes, and guiding personalized therapies. In psoriasis, where the disease presentation and response to therapy can vary widely among individuals, identifying reliable biomarkers like miR-205, miR-155, and miR-210 can revolutionize patient care by tailoring treatments to the individual's biological profile. The Euretos translational research platform accelerates biomarker discovery by analyzing preloaded datasets, integrating clinical and genomic data, and using advanced algorithms to uncover patterns and associations. This data-driven approach enables researchers to identify and validate new biomarkers faster, helping to guide clinical decision-making and personalize therapy for better patient outcomes. Join us in exploring how data-driven research can transform psoriasis care by identifying key biomarkers for treatment response. Academic research get free access. www.euretos.com #PsoriasisActionMonth #BiomarkerResearch #TranslationalScience #DrugDiscovery #AIinHealthcare #PrecisionMedicine

Using Systematic Reviews to improve Psoriasis preclinical research During this Psoriasis Action Month, we want to highlight the recent advancements in understanding this complex, chronic condition. A recent systematic review on preclinical models of psoriasis has provided key insights into the strengths and limitations of various research models, ranging from in vivo to in vitro and ex vivo [1]. This review emphasizes the need for robust, well-characterized models to accelerate the development of effective therapies. - The systematic review analyzed 45 studies on psoriasis models, offering a comprehensive evaluation of their application in drug discovery. - In vitro models were highlighted for their ease of use, particularly 3D models that closely mimic human skin. - The review also stressed the potential of future technologies like 3D bioprinting and organ-on-a-chip to improve these models and reduce the reliance on animal testing. The Role of Systematic Reviews in Translational Research: Systematic reviews are crucial in synthesizing vast amounts of data, identifying gaps in research, and guiding future studies. They help ensure that research is built on a solid foundation of existing knowledge, avoiding redundancy and focusing efforts on the most promising avenues. The Euretos research platform can significantly accelerate the systematic review process. By having automated the data collection, analysis, and synthesis, our platform reduces the time required to complete a review while uncovering deeper insights. This approach allows researchers to focus on the most critical aspects of their work, driving faster and more effective therapeutic discoveries. Join us in using the integration of AI in translational research to uncover new therapeutic strategies for psoriasis. With the right tools, we can push the boundaries of what's possible in healthcare. Get access at www.euretos.com #PsoriasisActionMonth #SystematicReview #TranslationalScience #DrugDiscovery #AIinHealthcare #PsoriasisTreatment [1] - Ubago-Rodríguez et al., "Challenges in Psoriasis Research: A Systematic Review of Preclinical Models," *Dermatology*, 2024. - doi/10.1159/000538993

Understanding dendritic cells’ impact on Psoriasis through scRNA-Seq Today we highlight the groundbreaking advancements in understanding the cellular mechanisms underlying Psoriasis. This chronic condition, affecting 2-3% of the global population, is driven by complex interactions between immune cells and skin cells. Recent studies using single-cell RNA sequencing (scRNA-seq) have unveiled detailed insights into these interactions, paving the way for novel therapeutic approaches [1]. Dendritic cells (DCs) in psoriatic lesions migrate to the dermal-epidermal junction, promoting collagen synthesis via the galectin pathway. This interaction increases tissue stiffness, which in turn drives basal cell proliferation. The mechano-chemical signaling cascade, particularly involving DC-secreted LGALS9 received by CD44+ dermal fibroblasts, leads to an upregulation of extracellular matrix (ECM) components like COL1A1, COL3A1, and COL6A1. This stiffer ECM environment is a crucial factor in basal cell hyperproliferation. The study identifies HMGB2 as a critical regulator of basal epidermal cell hyperproliferation in psoriatic lesions. The LGALS9-CD44 signaling axis is shown to be pivotal in this regulatory mechanism. Single-cell RNA sequencing allows researchers to dissect the heterogeneity within psoriatic lesions at an unprecedented resolution. This technology enables the identification of specific cell types, their states, and interactions, offering a detailed map of the disease at the cellular level. By leveraging these insights, translational research can develop targeted therapies that address the specific genetic and molecular mechanisms driving psoriasis. Understanding the role of different cell types and their interactions in psoriasis opens new avenues for therapeutic intervention. For instance, targeting the LGALS9-CD44 signaling pathway or modulating the expression of HMGB2 could provide novel treatment strategies. Data-driven approaches in translational research can thus accelerate the discovery of effective treatments tailored to the genetic and cellular landscape of psoriasis. Join us in advocating for continued genetic research and translational science to discover new therapeutic avenues for psoriasis. Together, we can transform insights into action, offering hope and improved outcomes for those affected by this challenging condition. Sign up to the Euretos Platform at www.euretos.com. #PsoriasisActionMonth #TranslationalScience #DrugDiscovery #PsoriasisTreatment #AIinHealthcare [1] Jiang et al., "The mechano-chemical circuit in fibroblasts and dendritic cells drives basal cell proliferation in psoriasis", *Cell Reports*, 2024. (https://lnkd.in/emrUjJfJ)

Unlocking New Therapeutic Pathways in Psoriasis through Genetic Research As we recognize Psoriasis Action Month this August, we want to highlight the critical role genetics play in understanding and treating psoriasis. Recent research has revealed how somatic mutations and environmental exposures like psoralen can shape the mutation landscape of psoriatic skin. [1] Psoriasis, a chronic inflammatory skin condition, exhibits a complex genetic backdrop that influences disease progression and response to treatment. Whole-exome sequencing studies have highlighted that the mutation burden in keratinocytes, the primary cells involved in psoriasis, is modestly affected by the disease. These studies have identified mutations in key driver genes such as NOTCH1, NOTCH2, TP53, FAT1, and PPM1D. Additionally, novel genetic associations were found in genes like GXYLT1, CHEK2, ZFP36L2, and EEF1A1, which are hypothesized to be selected for in squamous epithelium irrespective of disease status.  Understanding these genetic underpinnings is crucial. By exploring the somatic mutation landscapes in both lesional and non-lesional skin, scientists have uncovered how genetic alterations contribute to the disease's pathology and treatment response. This knowledge paves the way for targeted therapies that can address the specific genetic and molecular mechanisms at play in psoriasis. Data-driven translational research is instrumental in this endeavor. By leveraging comprehensive genetic data and advanced bioinformatics, we can better understand cell-type interactions and the impact of genetic variations on psoriasis. This approach not only enhances our understanding but also accelerates the development of innovative therapies tailored to individual genetic profiles. Join us in advocating for continued genetic research and translational science to discover new therapeutic avenues for psoriasis. Sign up for the Euretos Platform here. Academic researcher get free access. #PsoriasisActionMonth #GeneticResearch #TranslationalScience #DrugDiscovery #PsoriasisTreatment #AIinHealthcare [1] Nature Genetics: [Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin] (https://lnkd.in/e73BRaxZ)

This July we honor the legacy of Peyton Rous, the Nobel Prize laureate who discovered tumor-inducing viruses. His groundbreaking work laid the foundation for modern tumor virology and opened new avenues in cancer research. Rous's discovery of the Rous sarcoma virus (RSV) from a chicken sarcoma transformed our understanding of viral oncology and sarcoma biology. Peyton Rous's pioneering work in isolating a filterable agent from a sarcoma in the breast muscle of a hen, now known as RSV, was a monumental step in cancer research. This discovery demonstrated that viruses could induce tumors, fundamentally altering our approach to understanding cancer causation and progression. Rous's work was instrumental in the identification of oncogenes and the role of viruses in cancer, bridging the gap between biological and molecular eras. Rous's contributions highlight the critical importance of data-driven translational research in the fight against sarcoma. By utilizing advanced technologies like single-cell RNA sequencing and protein-protein interaction network analysis, researchers can uncover the complex interactions between viral and host proteins. Understanding these interactions is essential for identifying new therapeutic targets and developing effective treatments for sarcoma patients. For instance, investigating the protein-protein interaction networks between RSV proteins and host cell proteins can reveal potential mechanisms of oncogenesis and identify novel drug targets. Such studies not only enhance our understanding of sarcoma biology but also pave the way for innovative therapeutic strategies that can improve patient outcomes. With our AI Platform for translational research, we are committed to building on the legacy of researchers like Peyton Rous. Our platform leverages AI to analyze complex datasets, identify key molecular interactions, and accelerate the discovery of new therapies. By integrating patient-led research with advanced computational tools, we aim to uncover new insights into sarcoma and other cancers. This Sarcoma Awareness Month, let's celebrate the contributions of Peyton Rous and the ongoing advancements in sarcoma research. Together, we can drive forward the development of innovative treatments and improve the lives of patients affected by challenging diseases. #SarcomaAwarenessMonth #PeytonRous #TumorVirology #CancerResearch #TranslationalResearch #AIinHealthcare #SarcomaResearch #DrugDiscovery #SupportSarcomaPatients #HealthcareInnovation

A new Euretos Perspective article is now available! This month we highlight a groundbreaking study that uses single-cell RNA sequencing to explore osteosarcoma's molecular landscape, focusing on disulfidptosis, a novel cell death form linked to actin-cytoskeletal protein stress. Key highlights include: - Identification of crucial genes and proteins associated with disulfidptosis. - Insights into significant biological processes and pathways. - Understanding the complex network of intracellular communication in the osteosarcoma microenvironment. This research underscores the power of patient-led, data-driven translational research in uncovering new therapeutic targets and strategies. As we mark Sarcoma Awareness Month, let's emphasize the importance of continued investment in translational research to improve outcomes for patients. #EuretosPerspectives #TranslationalResearch #Osteosarcoma #SarcomaAwarenessMonth #SingleCellAnalysis #AIInHealthcare #CancerResearch #ScientificReports